Brigimadlin
- Generic Name
- Brigimadlin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H25Cl2FN4O3
- CAS Number
- 2095116-40-6
- Unique Ingredient Identifier
- 9A934ZAN94
- Associated Conditions
- -
- Associated Therapies
- -
How Pharmacists Can Make an Impact When Treating Dedifferentiated Liposarcoma With Brigimadlin
Liposarcoma, a common subtype of soft tissue sarcoma, includes dedifferentiated liposarcoma (DDLPS) with high MDM2 amplification. Brigimadlin, an MDM2-p53 antagonist, showed stable disease in 75% of patients in a phase 1a/1b study. A phase 2/3 Brightline-1 trial compares brigimadlin to doxorubicin in advanced DDLPS, aiming to identify optimal dosing and assess progression-free survival.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath